Haemonetics Corporation (HAE) Earnings Call Transcripts

Haemonetics Corporation's Latest Earnings Call - June 8, 2026

In Haemonetics Corporation's (HAE:US) earnings call for Q1 FY2027, the company reported a revenue growth of 10% year-over-year, exceeding its initial guidance of high single digits. Earnings growth was in the mid-20s percentage range, also surpassing expectations. However, management provided conservative guidance for FY2027, projecting organic growth of 3% to 6%, citing external pressures and a need for prudent forecasting. The operating income margin was reported at 18%, slightly below the targeted high 20s, indicating room for improvement.

Reported metrics

Guidance from management

Management maintained a conservative guidance for FY2027, projecting organic growth of 3% to 6%, reflecting external pressures and a focus on execution.

What management said

We've bought back stock meaningfully over the course of the past year. It's a second capital allocation priority behind the organic investment that we're making clinically and commercially in the business. We think the ROIC on that first year investments have been really attractive. A second priority is the buyback, right? We feel quite good about our balance sheet and where we are. We'll pay down debt opportunisti...

I think it's very reasonable. I'll just answer it in the here and the now. This is as good a collections environment, as I've seen over the last decade right? I think it's a very different economy for your typical donor than it is maybe for some other folks gathered here today. And so in that regard, our collectors are able to collect all the plasma they want at very favorable prices. Obviously, our yield enhanceme...

What analysts pressed on

Analysts expressed concerns over the conservative growth guidance and the potential impact of market dynamics on future performance. There were questions about the sustainability of revenue growth amid sector challenges.

Main topics on the call

• Revenue Growth Performance — Haemonetics achieved a revenue growth of 10% compared to the previous year, exceeding the guidance of high single digits. CEO Christopher Simon stated, 'We thought we would grow high single digits. We actually grew 10%.'
• Earnings Growth Exceeds Expectations — The company reported earnings growth in the mid-20s percentage range, outperforming the initial guidance of mid-teens. Simon noted, 'we said we would grow mid-teens on our earnings, we actually grew mid-20s.'
• Conservative FY2027 Guidance — Management provided a conservative outlook for FY2027, projecting organic growth of 3% to 6%. Simon emphasized the need for prudence, stating, 'I thought it was best to be highly prudent and keep our guidance conservativ...
• Operating Margin Performance — The operating income margin was reported at 18%, which fell short of the targeted high 20s. Simon mentioned, 'we actually got to 25 and change,' indicating a 700 basis point improvement but below expectations.

Read the full Haemonetics Corporation transcript (June 8, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 40 Haemonetics Corporation earnings call transcripts on record, spanning February 4, 2020 to August 6, 2026. Based on this history, Haemonetics Corporation reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

HAE

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

40

First call

February 4, 2020

Most recent

August 6, 2026

Reporting cadence

quarterly